Race Oncology Ltd. (AU:RAC) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Race Oncology Ltd has secured a $5.25 million R&D tax refund from the Australian Taxation Office for FY2024, thanks to the government’s incentive program. This funding will support the company’s efforts to accelerate the clinical development of its cancer treatment, RC220, which aims to meet significant unmet patient needs. Race Oncology is actively exploring partnerships to enhance global access to its innovative cancer therapies.
For further insights into AU:RAC stock, check out TipRanks’ Stock Analysis page.